Tirzepatide Dosing Protocol: Weekly Titration, Reconstitution & Research (2026)

Tirzepatide Quick Start

Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP and GLP-1 receptors — the first dual incretin agonist to reach market. It is studied for glucose regulation and body-composition endpoints. Its C20 fatty-diacid chain gives it a roughly weekly half-life, which is why every published schedule is once-weekly with a slow step-up designed to limit gastrointestinal effects.

Quick reference Approved molecule · research vial

Class

GIP / GLP-1 dual agonist

Formats

Vial (SubQ)

Half-life

~5 days (weekly dosing)

Schedule shape

Weekly, titrated

Vial sizes

20 mg · 40 mg

This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.

Tirzepatide Dosing Protocol

Tirzepatide is dosed once weekly with a step-up roughly every four weeks. The ladder below mirrors the titration schedule used for the approved molecule, shown here as research context rather than a personal dosing recommendation. The step-up exists because gastrointestinal effects cluster at initiation and after each increase.

Injection — Subcutaneous

Reconstituted vial, subcutaneous. Doses are in milligrams — the syringe-unit equivalent depends on the volume you reconstitute with, worked out below.

Step	Weekly dose	Typical duration
1 (start)	2.5 mg	4 weeks
2	5 mg	4 weeks
3	7.5 mg	4 weeks
4	10 mg	4 weeks
5	12.5 mg	4 weeks
6 (max)	15 mg	Maintenance

20 mg + 2 mL BAC → 10 mg/mL · 1 mg = 10 units · 8 doses per vial at the 2.5 mg step

The starting step is a tolerability dose, not a low-efficacy one — published schedules do not skip it. Moving up faster than four weeks per step is the single most common cause of the nausea and vomiting that ends a research protocol early.

Tirzepatide Reconstitution Guide

Both vial sizes reconstitute to the same 10 mg/mL working concentration if the volume is matched to the vial, which keeps the unit ladder above identical across both. Confirm the vial will physically hold the volume before drawing it.

Injection

Vial	BAC	Conc.	1 mg
20 mg	2 mL	10 mg/mL	10 u
40 mg	4 mL	10 mg/mL	10 u
40 mg	3 mL	13.3 mg/mL	7.5 u

Units are U-100 insulin-syringe units (100 u = 1.0 mL). The 40 mg vial at 3 mL is the fallback if it will not hold 4 mL — note the unit figures change.

Why 10 mg/mL

Matching the volume to the vial size keeps 1 mg = 10 units for both, so the same ladder works either way. Mixing the two conventions mid-cycle is a dosing error waiting to happen — write the volume on the vial.

Reconstitution steps

Inspect the vial. Confirm the label, expected milligram amount, and that the powder looks dry and intact.
Wipe the stoppers. Use an alcohol swab on both the bacteriostatic water and peptide vial stoppers.
Draw the chosen volume. 2 mL (20 mg vial) or 4 mL (40 mg vial) into the vial — this is the number that sets every concentration figure above.
Inject down the wall. Release the water slowly down the inside wall, not directly onto the powder.
Swirl, do not shake. Roll gently until dissolved. Shaking foams and can damage the peptide.
Verify clarity. Solution should be clear and colorless. Discard if cloudy or particulate.
Label and refrigerate. Note the date and volume added on the vial, then store at 2–8 °C. Do not freeze the reconstituted solution.

See the bacteriostatic water guide for diluent handling, or the reconstitution calculator to work any other volume.

How Tirzepatide Works

Tirzepatide activates two incretin receptors at once. GLP-1 receptor activity slows gastric emptying and increases glucose-dependent insulin secretion; GIP receptor activity is thought to add effects on adipose tissue and appetite signaling that GLP-1 alone does not produce. The dual mechanism is the basis for the larger effect sizes reported versus single-agonist comparators.

GLP-1 receptor

Glucose-dependent insulin release, slowed gastric emptying, appetite signaling.

GIP receptor

Adds adipose and appetite effects; the component that distinguishes it from single agonists.

Acylation

A C20 fatty-diacid chain drives albumin binding and the ~5-day half-life behind weekly dosing.

Open question

The relative contribution of the GIP arm in humans is still actively debated in the literature.

Who Should Avoid Tirzepatide

Human safety data for the approved molecule is extensive, but that does not transfer to research-grade material of unverified provenance. Categories where caution is most consistently flagged:

Personal or family MTC history

Rodent thyroid C-cell tumour findings drive a boxed contraindication for this class, including MEN 2.

Pregnancy & lactation

Not established as safe; the class is generally discontinued well before a planned pregnancy.

History of pancreatitis

Pancreatitis is a recognised class-level adverse event and a standard exclusion.

Severe gastroparesis or GI disease

The mechanism slows gastric emptying, which compounds pre-existing motility disorders.

Tirzepatide Side Effects & Safety

Gastrointestinal effects

Nausea, vomiting, diarrhoea and constipation are the dominant reported effects, concentrated at initiation and after each step-up.

Hypoglycaemia risk in combination

Low on its own because insulin release is glucose-dependent, but meaningfully higher alongside insulin or sulfonylureas.

Gallbladder events

Rapid weight reduction of any cause raises gallstone risk; reported across the class.

Quality-control risk

Research-grade material carries identity, purity and dosing-accuracy risk separate from the molecule — verify against a COA.

Timeline & What to Monitor

Timeframe	Commonly tracked	Notes
Week 1–4	Tolerability at the starting step	GI effects peak here; the step exists for this reason.
Week 4–20	Response at each step-up	Four weeks per step is the published cadence.
Month 3–6	Metabolic and body-composition endpoints	Where trial effect sizes separate from comparators.
Ongoing	Maintenance at the tolerated step	The maximum tolerated step is not always the maximum step.

These reference points come from the published trial programme for the approved molecule and are context, not predictions of individual outcomes.

Tirzepatide Evidence Context

Phase 3 programme

A large randomised programme underpins the approved indications, with active comparators including semaglutide.

Head-to-head data

Trials versus single GLP-1 agonists reported larger mean reductions for the dual agonist.

Cardiovascular outcomes

Outcome trials in this class have reported cardiovascular findings; read the specific trial rather than class summaries.

Open question

Long-term durability after discontinuation, and how much the GIP arm contributes, remain active questions.

Storage & Handling

State	Storage	Notes
Lyophilized (powder)	−20 °C, protected from light	More stable than reconstituted solution.
Reconstituted (liquid)	2–8 °C	Short-term; −20 °C for longer per the listing.
Appearance	Clear, colorless	Discard cloudy or particulate solutions.

Tirzepatide vs Semaglutide vs Retatrutide

Feature	Tirzepatide	Semaglutide	Retatrutide
Receptors	GIP + GLP-1	GLP-1	GIP + GLP-1 + glucagon
Status	Approved molecule	Approved molecule	Investigational (Phase 3)
Cadence	Weekly, titrated	Weekly, titrated	Weekly, titrated
Max step referenced	15 mg	2.4 mg	12 mg
Page	This page	Semaglutide	Retatrutide

Frequently Asked Questions

How is tirzepatide dosed?

Once weekly, starting at 2.5 mg and stepping up roughly every four weeks to a maximum of 15 mg. At 10 mg/mL, 1 mg is 10 units on a U-100 syringe, so the ladder runs 25 → 150 units.

What is the difference between the 20 mg and 40 mg vials?

Only the total content. Reconstituted to 2 mL and 4 mL respectively, both give 10 mg/mL, so the unit figures are identical. Confirm your vial holds 4 mL before using that volume.

How does it differ from semaglutide?

Semaglutide is a single GLP-1 agonist; tirzepatide adds GIP receptor activity. See the comparison table and the semaglutide page.

Why start so low?

The starting step is for tolerability. Gastrointestinal effects cluster at initiation and after each increase, and skipping steps is the most common reason a protocol is abandoned.

Are there legal restrictions?

GLP-1-class research peptides may be subject to state-level restrictions — California, New York, Mississippi and Tennessee are flagged on the product listing. Verifying local compliance is the buyer's responsibility.

Is this page medical advice?

No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.

Tirzepatide Formats & Sourcing

Tirzepatide is supplied as a lyophilized powder in two vial sizes. There is no pre-reconstituted pen or spray format for this compound. Batch-specific Certificates of Analysis are issued per lot.

Format	Supplied as
Vial — 20 mg	20 mg lyophilized powder
Vial — 40 mg	40 mg lyophilized powder

Strengths are listed as sold; confirm against the product page and the batch COA before calculating anything.

Reference material for this protocol, with batch COA:

View Tirzepatide on Spyro Peptides →

Purity ≥98% HPLC Batch COA available Research use only

References

Frías JP, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes. N Engl J Med (2021).
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med (2022).
Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab (2018).
Willard FS, et al. Tirzepatide bias at the GIP and GLP-1 receptors. JCI Insight (2020).
Product listing regulatory note, spyropeptides.com — state-level restrictions for GLP-1-class research peptides.